Efficacy and Safety of Bimekizumab in Patients with Moderate to Severe Plaque Psoriasis: Results from BE VIVID, a 52-Week Phase 3, Randomized, Double-Blinded, Ustekinumab- and Placebo-Controlled Study

Main Article Content

K Reich
K Papp
A Blauvelt
R Langley
A Armstrong
RB Warren
K Gordon
JF Merola
C Madden
M Wang
V Vanvoorden
M Lebwohl

Keywords

Psoriasis, Plaque Psoriasis, Biologic, Il-17A, Il-17F, Bimekizumab

Abstract

Abstract not available.

References

1. Durham L. Curr Rheumatol Reports 2015;17:55

2. Fujishima S. Arch Dermatol Res 2010;302:499–505

3. Johnston A. et al. J Immunol 2013;190:2252–62

4. Papp K. et al. JAAD 2018;79:277–86, NCT02905006

5. Blauvelt A. et al. AAD 2019 (OP11180), NCT03010527

6. FDA Briefing Document, Dermatologic and Opthalmic Drugs Advisory Committee, July 19 2016

7. Kerkhof PC. et al. JAAD 2016; 75:83–98

8. Australian Public Report for Ixekizumab, May 2017

9. Glatt S. et al. Br J Clin Pharm 2017;83(5):991–1001

10. Glatt S. et al. Ann Rheum Dis 2018;77:523–32.

Most read articles by the same author(s)

1 2 3 4 > >>